Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis
Abstract
:1. Introduction
2. Methods
2.1. Study Design
2.2. Data Sources
2.3. Search Methods
2.3.1. Search Terms for DAAs
2.3.2. Search Terms for Hepatitis C
2.3.3. Search Terms for Ribavirin
2.3.4. Search Terms for Hepatitis C Non-Genotype 1
2.4. Procedure for Selection of Studies
2.5. Eligibility
2.6. Key Definitions
2.7. Outcomes
2.8. Data Extraction
2.9. Assessing the Quality of Included Studies
2.10. Data Synthesis
Synthesis for Efficacy and Safety of DAAs With and Without Ribavirin
2.11. Ethics
3. Results
3.1. Search Results
3.2. Characteristics of Included Studies
3.3. Assessment of the Quality of Included Studies
3.4. Efficacy of Adding Ribavirin to DAAs in Achieving SVR at 12 Weeks—GRADE Assessment
3.5. Overall Effect Size and Consistency
3.6. Directness, Study Quality, and Publication Bias
3.7. Final GRADE Rating for the Efficacy of Adding Ribavirin to DAAs to Achieve SVR12
3.8. Sensitivity Analysis
3.9. Subgroup Analysis
3.10. SVR at 24 Weeks
3.11. Safety of Adding Ribavirin to DAAs
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
DAA | Direct-acting Antiviral |
HCV | Hepatitis C Virus |
Hb | Hemoglobin |
RR | Risk Ratio |
RCT | Randomized Controlled Trial |
SVR | Sustained Virological Response |
References
- World Health Organization. WHO Publishes Updated Guidance on Hepatitis C Infection—With New Recommendations on Treatment of Adolescents and Children, Simplified Service Delivery and Diagnostics; WHO: Geneva, Switzerland, 2022.
- Xue, W.; Liu, K.; Qiu, K.; Shen, Y.; Pan, Z.; Hu, P.; Peng, M.; Chen, M.; Ren, H. A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation? Int. J. Infect. Dis. 2019, 83, 56–63. [Google Scholar] [CrossRef] [PubMed]
- Pockros, P.J. Direct-Acting Antivirals for the Treatment of Hepatitis C Virus Infection. Available online: https://www.uptodate.com/contents/direct-acting-antivirals-for-the-treatment-of-hepatitis-c-virus-infection (accessed on 24 March 2025).
- Pawlotsky, J.M.; Negro, F.; Aghemo, A.; Berenguer, M.; Dalgard, O.; Dusheiko, G.; Marra, F.; Puoti, M.; Wedemeyer, H.; European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020, 73, 1170–1218. [Google Scholar] [CrossRef] [PubMed]
- Zein, N.N. Clinical significance of Hepatitis C virus genotypes. Clin. Microbiol. Rev. 2000, 13, 223–235. [Google Scholar] [CrossRef] [PubMed]
- Bhattacharya, D.; Aronsohn, A.; Price, J.; Re, V.L.; the American Association for the Study of Liver Diseases–Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C guidance 2023 update: American association for the study of liver diseases—Infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Clin. Infect. Dis. 2023, ciad319. [Google Scholar] [CrossRef]
- Webster, G.; Barnes, E.; Brown, D.; Dusheiko, G. HCV genotypes—Role in pathogenesis of disease and response to therapy. Best Pract. Res. Clin. Gastroenterol. 2000, 14, 229–240. [Google Scholar] [CrossRef]
- Pabjan, P.; Brzdęk, M.; Chrapek, M.; Dziedzic, K.; Dobrowolska, K.; Paluch, K.; Garbat, A.; Błoniarczyk, P.; Reczko, K.; Stępień, P.; et al. Are there still difficult-to-treat patients with chronic hepatitis C in the era of direct-acting antivirals? Viruses 2022, 14, 96. [Google Scholar] [CrossRef]
- Derbala, M.; Amer, A.; Bener, A.; Lopez, A.C.; Omar, M.; El Ghannam, M. Pegylated interferon-alpha 2b-ribavirin combination in egyptian patients with genotype 4 chronic hepatitis. J. Viral Hepat. 2005, 12, 380–385. [Google Scholar] [CrossRef]
- Lefkowitz, E.J.; Dempsey, D.M.; Hendrickson, R.C.; Orton, R.J.; Siddell, S.G.; Smith, D.B. Virus taxonomy: The database of the International Committee on Taxonomy of Viruses (ICTV). Nucl. Acids Res. 2018, 46, D708–D717. [Google Scholar] [CrossRef] [PubMed]
- Graham, C.S.; Muir, A.J. Management of Chronic Hepatitis C Virus Infection: Antiviral Retreatment Following Relapse in Adults. Available online: https://www.uptodate.com/contents/management-of-chronic-hepatitis-c-virus-infection-antiviral-retreatment-following-relapse-in-adults?search=Management%20of%20chronic%20hepatitis%20C%20virus%20infection%3A%20Antiviral%20retreatment%20following%20relapse%20in%20adults&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1 (accessed on 24 March 2025).
- Chan, A.; Patel, K.; Naggie, S. Genotype 3 infection: The last stand of hepatitis C virus. Drugs 2017, 77, 131–144. [Google Scholar] [CrossRef]
- HCV Guidance; American Association for the Study of Liver Disease. Retreatment of Persons in Whom Prior Therapy Failed. Available online: https://www.hcvguidelines.org/treatment-experienced (accessed on 24 March 2025).
- Te, H.S.; Randall, G.; Jensen, D.M. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol. Hepatol. N. 2007, 3, 218–225. [Google Scholar]
- El-Kassas, M.; Emadeldeen, M.; Hassany, M.; Esmat, G.; Gomaa, A.A.; El-Raey, F.; Congly, S.E.; Liu, H.; Lee, S.S. A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C. J. Hepatol. 2023, 79, 314–320. [Google Scholar] [CrossRef] [PubMed]
- Sulkowski, M.; Hezode, C.; Gerstoft, J.; Vierling, J.M.; Mallolas, J.; Pol, S.; Kugelmas, M.; Murillo, A.; Weis, N.; Nahass, R.; et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus Co-infection (C-WORTHY): A randomised, open-label phase 2 trial. Lancet 2015, 385, 1087–1097. [Google Scholar] [CrossRef] [PubMed]
- Mooney, K.; Melvin, M.; Douglas, T. Ribavirin: The need for exposure precautions. Clin. J. Oncol. Nurs. 2014, 18, E93–E96. [Google Scholar] [CrossRef]
- U.S. Food and Drug Administration. Sustiva (Efavirenz) Prescribing Information (NDA 021511, s023). 2011. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021511s023lbl.pdf (accessed on 1 April 2025).
- Curry, M.P.; O’Leary, J.G.; Bzowej, N.; Muir, A.J.; Korenblat, K.M.; Fenkel, J.M.; Reddy, K.R.; Lawitz, E.; Flamm, S.L.; Schiano, T.; et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N. Engl. J. Med. 2015, 373, 2618–2628. [Google Scholar] [CrossRef] [PubMed]
- Kwo, P.; Gane, E.J.; Peng, C.Y.; Pearlman, B.; Vierling, J.M.; Serfaty, L.; Buti, M.; Shafran, S.; Stryszak, P.; Lin, L.; et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2017, 152, 164–175.e4. [Google Scholar] [CrossRef]
- Bansal, S.; Singal, A.K.; McGuire, B.M.; Anand, B.S. Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J. Hepatol. 2015, 7, 806–813. [Google Scholar] [CrossRef]
- Suwanthawornkul, T.; Anothaisintawee, T.; Sobhonslidsuk, A.; Thakkinstian, A.; Teerawattananon, Y. Efficacy of second generation direct-acting antiviral agents for treatment naïve hepatitis C genotype 1: A systematic review and network meta-analysis. PLoS ONE 2015, 10, e0145953. [Google Scholar] [CrossRef]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Syst. Rev. 2021, 10, 89. [Google Scholar] [CrossRef]
- Li, H.C.; Lo, S.Y. Hepatitis C virus: Virology, diagnosis and treatment. World J. Hepatol. 2015, 7, 1377–1389. [Google Scholar] [CrossRef]
- Salmon, D.; Trimoulet, P.; Gilbert, C.; Solas, C.; Lafourcade, E.; Chas, J.; Piroth, L.; Lacombe, K.; Katlama, C.; Peytavin, G.; et al. Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World J. Hepatol. 2018, 10, 856–866. [Google Scholar] [CrossRef]
- Burgess, S.V.; Hussaini, T.; Yoshida, E.M. Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis C in the era of new oral direct-acting antivirals: A concise review. Ann. Hepatol. 2016, 15, 154–159. [Google Scholar] [CrossRef] [PubMed]
- Wu, P.S.; Chang, T.S.; Lu, S.N.; Su, H.J.; Chang, S.Z.; Hsu, C.W.; Chen, M.Y. An investigation of the side effects, patient feedback, and physiological changes associated with direct-acting antiviral therapy for hepatitis C. Int. J. Environ. Res. Public Health 2019, 16, 4981. [Google Scholar] [CrossRef] [PubMed]
- Stone, J.C.; Glass, K.; Clark, J.; Ritskes-Hoitinga, M.; Munn, Z.; Tugwell, P.; Doi, S.A.R. The methodological standards for epidemiological research (MASTER) scale demonstrated a unified framework for bias assessment. J. Clin. Epidemiol. 2021, 134, 52–64. [Google Scholar] [CrossRef] [PubMed]
- Doi, S.A.; Thalib, L. A quality-effects model for meta-analysis. Epidemiology 2008, 19, 94–100. [Google Scholar] [CrossRef]
- Doi, S.A.R.; Furuya-Kanamori, L.; Thalib, L.; Barendregt, J.J. Meta-analysis in evidence-based healthcare: A paradigm shift away from random effects is overdue. Int. J. Evid.-Based Health 2017, 15, 152–160. [Google Scholar] [CrossRef]
- Stone, J.C.; Glass, K.; Munn, Z.; Tugwell, P.; Doi, S.A.R. Comparison of bias adjustment methods in meta-analysis suggests that quality effects modeling may have less limitations than other approaches. J. Clin. Epidemiol. 2020, 117, 36–45. [Google Scholar] [CrossRef]
- Hedeker, D.; Gibbons, R.D. A random-effects ordinal regression model for multilevel analysis. Biometrics 1994, 50, 933–944. [Google Scholar] [CrossRef]
- Higgins, J.P.; Green, S.; Ben Van Den, A. Cochrane handbook for systematic reviews of interventions. Int. Coach. Psychol. Rev. 2020, 15, 123–125. [Google Scholar] [CrossRef]
- Furuya-Kanamori, L.; Barendregt, J.J.; Doi, S.A.R. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int. J. Evid.-Based. Health 2018, 16, 195–203. [Google Scholar] [CrossRef]
- Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [Google Scholar] [CrossRef]
- Guyatt, G.; Oxman, A.D.; Akl, E.A.; Kunz, R.; Vist, G.; Brozek, J.; Norris, S.; Falck-Ytter, Y.; Glasziou, P.; DeBeer, H. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J. Clin. Epidemiol. 2011, 64, 383–394. [Google Scholar] [CrossRef] [PubMed]
- Asahina, Y.; Itoh, Y.; Ueno, Y.; Matsuzaki, Y.; Takikawa, Y.; Yatsuhashi, H.; Genda, T.; Ikeda, F.; Matsuda, T.; Dvory-Sobol, H. Ledipasvir-sofosbuvir for treating japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int. 2018, 38, 1552–1561. [Google Scholar] [CrossRef] [PubMed]
- Esmat, G.; Elbaz, T.; El Raziky, M.; Gomaa, A.; Abouelkhair, M.; Gamal El Deen, H.; Sabry, A.; Ashour, M.; Allam, N.; Abdel-Hamid, M.; et al. Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. J. Hepatol. 2017, 68, 53–62. [Google Scholar] [CrossRef] [PubMed]
- Esteban, R.; Pineda, J.A.; Calleja, J.L.; Casado, M.; Rodríguez, M.; Turnes, J.; Morano Amado, L.E.; Morillas, R.M.; Forns, X.; Pascasio Acevedo, J.M.; et al. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology 2018, 155, 1120–1127.e4. [Google Scholar] [CrossRef]
- Foster, G.R.; Afdhal, N.; Roberts, S.K.; Bräu, N.; Gane, E.J.; Pianko, S.; Lawitz, E.; Thompson, A.; Shiffman, M.L.; Cooper, C.; et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med. 2015, 373, 2608–2617. [Google Scholar] [CrossRef]
- Foster, G.R.; Agarwal, K.; Cramp, M.E.; Moreea, S.; Barclay, S.; Collier, J.; Brown, A.S.; Ryder, S.D.; Ustianowski, A.; Forton, D.M.; et al. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. Hepatology 2018, 67, 2113–2126. [Google Scholar] [CrossRef]
- Pianko, S.; Flamm, S.L.; Shiffman, M.L.; Kumar, S.; Strasser, S.I.; Dore, G.J.; McNally, J.; Brainard, D.M.; Han, L.; Doehle, B.; et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: A randomized trial. Ann. Intern. Med. 2015, 163, 809–817. [Google Scholar] [CrossRef]
- Shiha, G.; Esmat, G.; Hassany, M.; Soliman, R.; Elbasiony, M.; Fouad, R.; Elsharkawy, A.; Hammad, R.; Abdel-Razek, W.; Zakareya, T.; et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: Results from a randomised phase III study in egypt. Gut 2019, 68, 721–728. [Google Scholar] [CrossRef]
- Lawitz, E.; Yoshida, E.M.; Buti, M.; Vierling, J.M.; Almasio, P.L.; Bruno, S.; Ruane, P.J.; Hassanein, T.I.; Lalezari, J.P.; Mullhaupt, B.; et al. Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/MK-8408 with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2 or 3 infection (part B of C-CREST-1 &2). Hepatology 2016, 64, 60A. [Google Scholar]
- Elshafie, S.; Trivedi-Kapoor, R.; Ebell, M. Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis. J. Clin. Pharm. Ther. 2022, 47, 1149–1158. [Google Scholar] [CrossRef]
- Ren, X.D.; Fu, X.; He, Y.Q.; Li, C.Y.; Guo, M.; Qiao, M. Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis. Medicine 2022, 101, e31183. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, H.; Abushouk, A.I.; Attia, A.; Gadelkarim, M.; Gabr, M.; Negida, A.; Abdel-Daim, M.M. Safety and Efficacy of Sofosbuvir plus Velpatasvir with or without Ribavirin for Chronic Hepatitis C Virus Infection: A systematic review and meta-analysis. J. Infect. Public Health 2018, 11, 156–164. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, H.; Abushouk, A.I.; Menshawy, A.; Mohamed, A.; Negida, A.; Loutfy, S.A.; Abdel-Daim, M.M. Safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: A systematic review and meta-analysis. Clin. Drug Investig. 2017, 37, 1009–1023. [Google Scholar] [CrossRef] [PubMed]
- Liao, H.T.; Tan, P.; Huang, J.W.; Yuan, K.F. Ledipasvir + sofosbuvir for liver transplant recipients with recurrent hepatitis C: A systematic review and meta-analysis. Transplant. Proc. 2017, 49, 1855–1863. [Google Scholar] [CrossRef]
- American Association for the Study of Liver Diseases-Infectious Diseases Society of America. (n.d.). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. (Updated 24 October 2022). Available online: https://www.hcvguidelines.org/treatment-experienced (accessed on 1 April 2025).
- Chopra, S.; Arora, S. Patient Evaluation and Selection for Antiviral Therapy for Chronic Hepatitis C Virus Infection. Available online: https://www.uptodate.com/contents/patient-evaluation-and-selection-for-antiviral-therapy-for-chronic-hepatitis-c-virus-infection (accessed on 24 March 2025).
- Loo, J.H.; Xu, W.X.F.; Low, J.T.; Tay, W.X.; Ang, L.S.; Tam, Y.C.; Thurairajah, P.H.; Kumar, R.; Wong, Y.J. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. World J. Hepatol. 2022, 14, 1248–1257. [Google Scholar] [CrossRef]
Author/ Publication Year | Country | Follow-Up Period (Months) | Type of Prior Treatment | GT Included | Sample Size | Inv Group Regimen + Duration | Control Group Regimen + Duration | Cirrhosis |
---|---|---|---|---|---|---|---|---|
Shiha 2019 (cohort 3) [43] | Egypt | 3 | IFN | GT4 | 74 | LDV/SOF + RBV for 12 or 16 weeks | LDV/SOF for 12 weeks | 28% int, 26% in control |
Esmat 2017 [38] | Egypt | 6 | IFN + RBV | GT4 | 149 | RDV/SOF + RBV for 12 weeks | RDV/SOF for 12 weeks | 47% in total TE |
Esteban, 2018 [39] | Spain | 3 | DAA +PEG-IFN + RBV/PEG-IFN+ RBV | GT3 | 55 | SOF/VEL + RBV for 12 weeks | SOF/VEL for 12 weeks | 100% |
Curry, 2015 [19] | USA | 6 | DAA/PEG-IFN + RBV | GT1 (1a, 1b), GT2, GT3, GT4 | 41 | SOF/VEL + RBV for 12 weeks | SOF/VEL for 12 or 24 weeks | 100% (decompensated) |
Asahina, 2015 [37] | Japan | 6 | DAA/PEG-IFN | GT2 (2a, 2b, and 2c) | 68 | SOF + RBV for 12 weeks | LDV/SOF for 12 weeks | 13% int, 15% control (for TN and TE) |
Foster, 2015 [40] | USA, Canada, Europe, Australia and New Zealand | 6 | DAA + PEG-IFN + RBV and PEG-IFN + RBV and others | GT3 | 142 | SOF + RBV for 24 weeks | SOF/VEL for 12 weeks | 52% in int, 55% in control |
Pianko, 2015 [42] | Australia, New Zealand, USA | 3 | IFN | GT3, GT1 | 210 | SOF/VEL + RBV for 12 weeks | SOF/VEL for 12 weeks | 50% in int, 49% in control |
Foster, 2017 [41] | UK | 6 | PEG-IFN/RBV | GT3 | 35 | SOF/EBR/GZR + RBV for 12 weeks | SOF/EBR/GZR for 12 or 16 weeks | 100% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hamran, S.; Al-Rajhi, A.A.; Jasim, K.; Al-Theyab, M.A.; Elahtam, M.; Al-Hail, M.K.; Al-Fahaidi, W.; Khamis, Y.A.; Dweidri, Y.; Elzouki, A.-N.; et al. Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis. Diseases 2025, 13, 138. https://doi.org/10.3390/diseases13050138
Hamran S, Al-Rajhi AA, Jasim K, Al-Theyab MA, Elahtam M, Al-Hail MK, Al-Fahaidi W, Khamis YA, Dweidri Y, Elzouki A-N, et al. Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis. Diseases. 2025; 13(5):138. https://doi.org/10.3390/diseases13050138
Chicago/Turabian StyleHamran, Shahd, Amani A. Al-Rajhi, Kawthar Jasim, Majed A. Al-Theyab, Mohamed Elahtam, Mooza K. Al-Hail, Wadha Al-Fahaidi, Yaman A. Khamis, Yara Dweidri, Abdel-Naser Elzouki, and et al. 2025. "Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis" Diseases 13, no. 5: 138. https://doi.org/10.3390/diseases13050138
APA StyleHamran, S., Al-Rajhi, A. A., Jasim, K., Al-Theyab, M. A., Elahtam, M., Al-Hail, M. K., Al-Fahaidi, W., Khamis, Y. A., Dweidri, Y., Elzouki, A.-N., & Chivese, T. (2025). Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis. Diseases, 13(5), 138. https://doi.org/10.3390/diseases13050138